Auvelity works by targeting the glutamate system in the brain, a fundamentally different approach from traditional antidepressants that focus on serotonin, norepinephrine, or dopamine. It combines two active ingredients, dextromethorphan and bupropion, that work together in a carefully designed partnership: dextromethorphan acts on brain receptors involved in mood regulation, while bupropion slows the breakdown of dextromethorphan so it stays active long enough to have a therapeutic effect. This dual mechanism is what makes Auvelity the first FDA-approved oral antidepressant to work through the glutamate pathway.
A Different Target Than Traditional Antidepressants
Most antidepressants on the market, including SSRIs and SNRIs, work by increasing levels of monoamine neurotransmitters like serotonin and norepinephrine. While these drugs help many people, they come with well-known limitations: remission rates are relatively low, and it typically takes weeks to months before patients feel meaningful relief. That delay exists because boosting monoamine levels is an indirect route to changing brain signaling patterns.
Auvelity takes a more direct path. Its primary active ingredient, dextromethorphan, blocks a specific type of receptor called the NMDA receptor and activates another called the sigma-1 receptor. Both of these are involved in how the brain processes glutamate, the most abundant excitatory chemical messenger in the nervous system. Glutamate plays a central role in how brain cells communicate, form new connections, and adapt over time. By modulating glutamate signaling rather than just raising serotonin levels, Auvelity appears to produce faster changes in mood-related brain circuits.
Why Auvelity Needs Two Ingredients
Dextromethorphan on its own wouldn’t work as an antidepressant. The reason is simple: your liver breaks it down too quickly. An enzyme called CYP2D6 metabolizes dextromethorphan so rapidly that it never reaches high enough levels in the bloodstream to affect brain chemistry in a meaningful way. This is why dextromethorphan has been available for decades as a cough suppressant without anyone noticing antidepressant effects at standard doses.
Bupropion solves this problem. It powerfully inhibits CYP2D6, and so do its breakdown products that accumulate in the body over time. One of these metabolites, hydroxybupropion, reaches blood levels five to ten times higher than bupropion itself and is an even stronger inhibitor of the enzyme. When bupropion and dextromethorphan are taken together, dextromethorphan exposure roughly quadruples. Modeling studies predict a 4-fold increase in total drug exposure and a 3-fold increase in peak blood levels of dextromethorphan after steady dosing.
Bupropion also contributes its own antidepressant activity. It blocks the reuptake of norepinephrine and dopamine, two neurotransmitters linked to motivation, energy, and focus. Both dextromethorphan and bupropion also activate sigma-1 receptors, which can modulate both glutamate and monoamine signaling. So the combination isn’t just about keeping dextromethorphan in the bloodstream longer. The two drugs appear to complement each other across multiple brain pathways.
How Fast It Works
One of the most notable features of Auvelity is its speed. In the GEMINI phase 3 clinical trial, patients taking the combination showed statistically significant improvement in depression scores compared to placebo at just one week. That’s considerably faster than the typical timeline for SSRIs, which often require four to six weeks before patients notice a clear difference.
By the end of the six-week trial, patients on Auvelity saw an average 15.9-point drop on the standard depression rating scale used in clinical research, compared to a 12-point drop in the placebo group. A phase 2 trial confirmed similar findings, with significant separation from placebo appearing as early as week two and continuing through the end of treatment. This rapid onset likely reflects the fact that glutamate-targeted treatments can change brain signaling more quickly than drugs that work through slower monoamine pathways.
How You Take It
Each Auvelity tablet contains 45 mg of dextromethorphan and 105 mg of bupropion in an extended-release formulation. You start with one tablet daily for the first three days, then increase to one tablet twice daily from day four onward. This short ramp-up period allows bupropion to build up in your system and begin inhibiting CYP2D6 before you reach the full dose, which helps dextromethorphan achieve therapeutic levels more smoothly.
Common Side Effects
In pooled data from six-week controlled trials involving 364 patients on Auvelity and 164 on placebo, the most frequently reported side effects were:
- Dizziness: 13.7% on Auvelity vs. 6.1% on placebo
- Nausea: 10.2%
- Headache: 6.6% vs. 3.7% on placebo
- Dry mouth: 5.5% vs. 2.4% on placebo
- Sleepiness: 5.2% vs. 3.0% on placebo
Dizziness is the most common complaint and occurs at more than double the rate seen with placebo. For most people, these side effects are mild and tend to improve as the body adjusts. Nausea and dizziness are often most noticeable during the first week of treatment.
Who Should Not Take Auvelity
Because bupropion lowers the seizure threshold, Auvelity is contraindicated in people with seizure disorders. It’s also contraindicated in anyone with a current or past diagnosis of bulimia or anorexia nervosa, since higher seizure rates have been observed in these patients with bupropion.
You cannot take Auvelity if you are withdrawing abruptly from alcohol, benzodiazepines, barbiturates, or anti-seizure medications, as this combination raises seizure risk further. It’s also strictly off-limits if you’ve taken an MAOI within the past 14 days, due to the risk of dangerous spikes in blood pressure and serotonin syndrome. This includes less obvious MAOIs like the antibiotic linezolid and intravenous methylene blue. Anyone with a known allergy to either bupropion or dextromethorphan should also avoid it.